

**BY E-MAIL**

April 17, 2024

BSE Ltd. Phiroze Jeejeebhoy Towers 27 <sup>th</sup> Floor, Dalal Street Mumbai 400 023 E-mail: corp.relations@bseindia.com	The National Stock Exchange of India Ltd. Exchange Plaza, 5 <sup>th</sup> Flr, Plot # C/1 G Block, Bandra-Kurla Complex, Bandra (E), Mumbai 400 051. E-mail : takeover@nse.co.in
--	--

Dear Sir,


**Re: Declaration under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we are enclosing herewith our disclosure for allotment to us of 26,00,000 equity shares of Rs.10/- each of M/s. Lyka Labs Limited (BSE Scrip Code : 500259 / NSE Scrip Code : LYKALABS) @ Rs. 139.50 per share allotted to us on 16<sup>th</sup> April, 2024 on conversion of balance warrants held by us in the said company.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully  
For and on behalf Ipca Laboratories Limited



Harish P. Kamath  
Company Secretary

Encl: a/a

Cc: Lyka Labs Ltd.  
4801/B & 4802/A, GIDC Industrial Estate,  
Ankleshwar – 393 002, Gujarat  
E-mail id : companysecretary@lykalabs.com

**Ipca Laboratories Ltd.**  
[www.ipca.com](http://www.ipca.com)

**Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Part A – Details of Acquisition**

Name of the Target Company (TC)	Lyka Labs Limited (BSE Scrip Code : 500259 / NSE Scrip Code : LYKALABS)		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the Acquirer	<b>Acquirer</b> Ipca Laboratories Limited <b>Person Acting in Concert</b> Mr. Pranay Godha Mrs. Neetu Godha Mrs. Usha Godha Mrs. Bhawna Godha Mr. Premchand Godha		
Whether the acquirer belongs to Promoter / Promoter Group	Yes. Acquirer belongs to Promoter / Promoter Group		
Name(s) of the Stock Exchange(s) where the shares of TC are listed	BSE Ltd. (BSE); and The National Stock Exchange of India Ltd. (NSE)		
Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t total diluted share / voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of acquirer along with PACs of:</b>			
a. Shares carrying voting rights			
i. Ipca Laboratories Ltd.	1,20,24,923	36.34%	36.34%
ii. Mr. Pranay Godha	3,00,000	0.91%	0.91%
iii. Mrs. Neetu Godha	10,000	0.03%	0.03%
iv. Mrs. Usha Godha	10,686	0.03%	0.03%
v. Mrs. Bhawna Godha	6,000	0.02%	0.02%
vi. Mr. Premchand Godha	10,900	0.03%	0.03%
<b>TOTAL</b>	<b>1,23,62,509</b>	<b>37.36%</b>	<b>37.36%</b>
b. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
c. Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	50,00,000**	**	**
e. Total (a+b+c+d)	<b>1,23,62,509</b>	<b>37.36%</b>	<b>37.36%</b>



**Ipca Laboratories Ltd.**


[www.ipca.com](http://www.ipca.com)

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
<b>Details of Acquisition /Sale</b>			
a. Shares carrying voting rights acquired			
i. Ipca Laboratories Ltd.	26,00,000	7.28%	7.28%
b. VRs acquired otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / Convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	Nil	Nil	Nil
d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total (a+b+c+/-d)	26,00,000	7.28%	7.28%
<b>After the acquisition, holding of</b>			
a. Shares carrying voting rights			
i. Ipca Laboratories Ltd.	1,46,24,923	40.98%	40.98%
ii. Mr. Pranay Godha	3,00,000	0.84%	0.84%
iii. Mrs. Neetu Godha	10,000	0.03%	0.03%
iv. Mrs. Usha Godha	10,686	0.03%	0.03%
v. Mrs. Bhawna Godha	6,000	0.02%	0.02%
vi. Mr. Premchand Godha	10,900	0.03%	0.03%
<b>TOTAL</b>	<b>1,49,62,509</b>	<b>41.93%</b>	<b>41.93%</b>
b. VRs otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total (a+b+c+d)	Nil	Nil	Nil


**Ipca Laboratories Ltd.**
[www.ipca.com](http://www.ipca.com)

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Mode of acquisition (eg. Open market / public issue/rights issue/preferential allotment/inter-se transfer etc.)	Conversion of Warrants into Equity Shares		
Date of acquisition of shares or date of receipt of intimation of allotment of shares/VR/warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC	16 <sup>th</sup> April, 2024		
Equity share capital/total voting capital of the TC before the said acquisition	3,30,90,000	100%	100%
Equity share capital /total voting capital of the TC after the said acquisition	3,56,90,000	100%	100%
Total diluted share/voting capital of the TC after the said acquisition	3,56,90,000	100%	100%

\*\* Pursuant to the necessary special resolution passed by its members, M/s. Lyka Labs Limited has also allotted 50,00,000 convertible warrants to the Company at its board meeting held on 15<sup>th</sup> March, 2023. Each warrant allotted is convertible into one equity share of Rs. 10/- each of M/s. Lyka Labs Limited @ Rs. 139.50 per share within a period of 18 months from the date of allotment, at the option of the allottee, either wholly or in tranches. Out of these warrants, balance 26,00,000 warrants are now converted and allotted to us. With this conversion, all the aforesaid warrants allotted to us are converted into equity shares.

**Signature of the acquirer / Authorised Signatory:**

For Ipca Laboratories Ltd.



Harish P. Kamath  
 Company Secretary

Place: Mumbai

Date: 17<sup>th</sup> April, 2024